Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 126 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Norvasc Clear all

Conditions: Essential Hypertension
Interventions: XOMA 985, Amlodipine Besylate, Perindopril Erbumine; Drug
Lead sponsor: Symplmed Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 837 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 48
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Glendale, Arizona + 45 more

Conditions: Hypertension
Interventions: amlodipine and olmesartan, losartan and HCTZ; Drug
Lead sponsor: InVasc Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tucker, Georgia

Conditions: Hypertension
Interventions: Hydrochlorothiazide, Lisinopril, Lisinopril and Hydrochlorothiazide, Nifedipine XL, Metoprolol tartrate, Atenolol, Valsartan, Doxazosin, Clonidine, Hydralazine, Metoprolol succinate, Amlodipine; Drug
Lead sponsor: Creighton University; Other
Eligibility: 25 Years to 80 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hypertension
Interventions: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg, telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg; Drug
Lead sponsor: George Medicines PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 1,385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more

Conditions: Healthy
Interventions: Amlodipine Besylate, Norvasc; Drug
Lead sponsor: Torrent Pharmaceuticals Limited; Industry
Eligibility: 18 Years to 45 Years
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: HIV Infections, Cardiovascular Diseases, Hypertension
Interventions: Indinavir sulfate, Ritonavir, Amlodipine, Diltiazem HCl; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2004
U.S. locations: 9
States / cities: San Francisco, California • Stanford, California • Denver, Colorado + 6 more

Conditions: Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions: Amlodipine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
Interventions: Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP; Drug · Other
Lead sponsor: Rong Zhang; Other
Eligibility: 60 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ); Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Little Rock, Arkansas • South Miami, Florida • Mattapan, Massachusetts + 2 more

Conditions: Hypertension
Interventions: valsartan+amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension, Stage 2 Hypertension, Diabetes
Interventions: Valturna, Amlodipine, Chlorthalidone, Placebo of Valturna Tablet, Placebo Capsule; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 95
States / cities: Athens, Alabama • Florence, Alabama • Huntsville, Alabama + 78 more

Conditions: Pediatric Hypertension
Interventions: NICHE method, Usual care, Amlodipine, Lisinopril, Hydrochlorothiazide, Losartan; Other · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 10 Years to 22 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension, Mineralocorticoid Excess
Interventions: Eplerenone, Amlodipine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 17 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Amlodipine/benazepril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 275 participants
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Drug
Lead sponsor: Novartis; Industry
Eligibility: 55 Years and older
Enrollment: 11,506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: Olmesartan medoxomil, Hydroclorothiazide, Benazepril, Amlodipine; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 20
States / cities: Mobile, Alabama • Long Beach, California • Los Angeles, California + 17 more

Conditions: Hypertension, Type 2 Diabetes Mellitus
Interventions: Nebivolol, Metoprolol ER, HCTZ; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 62
States / cities: Athens, Alabama • Huntsville, Alabama • Bell Gardens, California + 54 more

Conditions: Heart Failure With Preserved Ejection Fraction, Hypertension
Interventions: Amlodipine Besylate, Metoprolol Succinate; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Essential Hypertension
Interventions: Aliskiren, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension
Interventions: Amlodipine 5 mg, Placebo, Telmisartan 20 mg, Telmisartan 40 mg, Amlodipine 10 mg, Telmisartan 80 mg, Amlodipine 2.5 mg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 101
States / cities: Fairhope, Alabama • Huntsville, Alabama • Chandler, Arizona + 81 more

Conditions: Hypertension, Diastolic Dysfunction
Interventions: valsartan, amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: USA, New Jersey

Conditions: Hypertension, Dyslipidemia
Interventions: Caduet; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 34
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Garden Grove, California + 30 more

Conditions: Hypertension, Dyslipidemia
Interventions: Amlodipine/Atorvastatin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 106
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 73 more

Conditions: Hypertension
Interventions: Valsartan and hydrochlorothiazide (HCTZ) - monotherapy, Valsartan and amlodipine, Usual care, Valsartan, Valsartan and hydrochlorothiazide (HCTZ) - combination arm; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Perindopril Amlodipine for the Treatment of Hypertension

Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome

Black Education and Treatment of Hypertension (BEAT HTN)

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 18 Fed, Healthy Adult Subjects

Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers

Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension

One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

N-of-1 Trials In Children With Hypertension

MR Antagonist and LSD1

Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

Caduet in an Untreated Subject Population

Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population

Valsartan Intensified Primary Care Reduction of Blood Pressure Study